Vasoactive intestinal peptide increases hepatic transduction and reduces innate immune response following administration of helper-dependent Ad

Molecular Therapy

Volumn 18, Issue 7, 2010, Pages 1339-1345

  Vetrini, Francesco ^a   Brunetti Pierri, Nicola ^a   Palmer, Donna J ^a   Bertin, Terry ^a   Grove, Nathan C ^a   Finegold, Milton J ^a   Ng, Philip ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA GALACTOSIDASE; HELPER DEPENDENT ADENOVIRUS VECTOR; INTERLEUKIN 12; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENE FUNCTION; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; LIVER BLOOD FLOW; LIVER CELL; MALE; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM;

MUS;

EID: 77954243547     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.84     Document Type: Article

References (48)

1. Brunetti-Pierri, N, Stapleton, GE, Law, M, Breinholt, J, Palmer, DJ, Zuo, Y et al. (2009). Effcient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther 17: 327-333.
2. Brunetti-Pierri, N and Ng, P (2009). Progress towards liver and lung-directed gene therapy with helper-dependent adenoviral vectors. Curr Gene Ther 9: 329-340.
3. Brunetti-Pierri, N, Palmer, DJ, Beaudet, AL, Carey, KD, Finegold, M and Ng, P (2004). Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15: 35-46.
4. Morral, N, O'Neal, WK, Rice, K, Leland, MM, Piedra, PA, Aguilar-Córdova, E et al. (2002). Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 13: 143-154.
5. Nunes, FA, Furth, EE, Wilson, JM and Raper, SE (1999). Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther 10: 2515-2526.
6. Lievens, J, Snoeys, J, Vekemans, K, Van Linthout, S, de Zanger, R, Collen, D et al. (2004). The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther 11: 1523-1531.
7. Snoeys, J, Lievens, J, Wisse, E, Jacobs, F, Duimel, H, Collen, D et al. (2007). Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther 14: 604-612.
8. Brunetti-Pierri, N, Palmer, DJ, Mane, V, Finegold, M, Beaudet, AL and Ng, P (2005). Increased hepatic transduction with reduced systemic dissemination and proinfammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol Ther 12: 99-106.
9. Arranz, A, Juarranz, Y, Leceta, J, Gomariz, RP and Martínez, C (2008). VIP balances innate and adaptive immune responses induced by specifc stimulation of TLR2 and TLR4. Peptides 29: 948-956.
10. Chorny, A, Gonzalez-Rey, E, Ganea, D and Delgado, M (2006). Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation. Ann N Y Acad Sci 1070: 190-195.
11. Richardson, PD and Withrington, PG (1981). Liver blood fow. II. Effects of drugs and hormones on liver blood fow. Gastroenterology 81: 356-375.
12. Finke, U and Seifert, J (1986). Differential effects of gastrointestinal hormones on the blood fow of the alimentary tract of the dog. Res Exp Med (Berl) 186: 151-165.
13. Leister, I, Mbachu, EM, Post, S, Samel, ST, Stojanovic, T, Gutt, CN et al. (2002). Vasoactive intestinal polypeptide and gastrin-releasing peptide attenuate hepatic microvasculatory disturbances following intestinal ischemia and reperfusion. Digestion 66: 186-192.
14. Oda, M, Han, JY and Yokomori, H (2000). Local regulators of hepatic sinusoidal microcirculation: recent advances. Clin Hemorheol Microcirc 23: 85-94.
15. Oda, M, Azuma, T, Watanabe, N, Nishizaki, Y, Nishida, J, Ishii, K et al. (1990). Regulatory mechanisms of the hepatic microcirculation. Involvement of the contraction and dilatation of sinusoids and sinusoidal endothelial fenestrae. Prog Appl Microcirc 17:103-128.
16. Braet, F and Wisse, E (2002). Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 1: 1.
17. Delgado, M and Ganea, D (2000). Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol 165: 3051-3057.
18. Delgado, M and Ganea, D (2001). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-κB-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem 276: 369-380.
19. Delgado, M, Gomariz, RP, Martinez, C, Abad, C and Leceta, J (2000). Anti-infammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol 30: 3236-3246.
20. Yin, H, Cheng, H, Yu, M, Zhang, F, Lin, J, Gao, Y et al. (2005). Vasoactive intestinal peptide ameliorates synovial cell functions of collagen-induced arthritis rats by down-regulating NF-kappaB activity. Immunol Invest 34: 153-169.
21. Gomariz, RP, Arranz, A, Abad, C, Torroba, M, Martinez, C, Rosignoli, F et al. (2005). Time-course expression of Toll-like receptors 2 and 4 in infammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol 78: 491-502.
22. Abad, C, Martinez, C, Juarranz, MG, Arranz, A, Leceta, J, Delgado, M et al. (2003). Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124: 961-971.
23. Juarranz, Y, Abad, C, Martinez, C, Arranz, A, Gutierrez-Cañas, I, Rosignoli, F et al. (2005). Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 7: R1034-R1045.
24. Martinez, C, Abad, C, Delgado, M, Arranz, A, Juarranz, MG, Rodriguez-Henche, N et al. (2002). Anti-infammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci USA 99: 1053-1058.
25. Delgado, M and Ganea, D (2000). Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages. J Neuroimmunol 110: 97-105.
26. Muruve, DA, Barnes, MJ, Stillman, IE and Libermann, TA (1999). Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10: 965-976.
27. McCaffrey, AP, Fawcett, P, Nakai, H, McCaffrey, RL, Ehrhardt, A, Pham, TT et al. (2008). The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther 16: 931-941.
28. Borgland, SL, Bowen, GP, Wong, NC, Libermann, TA and Muruve, DA (2000). Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB. J Virol 74: 3941-3947.
29. Schnell, MA, Zhang, Y, Tazelaar, J, Gao, GP, Yu, QC, Qian, R et al. (2001). Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 3(5 Pt 1): 708-722.
30. Zhang, Y, Chirmule, N, Gao, GP, Qian, R, Croyle, M, Joshi, B et al. (2001). Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 3(5 Pt 1): 697-707.
31. Brunetti-Pierri, N, Ng, T, Iannitti, DA, Palmer, DJ, Beaudet, AL, Finegold, MJ et al. (2006). Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum Gene Ther 17: 391-404.
32. Kim, IH, Józkowicz, A, Piedra, PA, Oka, K and Chan, L (2001). Lifetime correction of genetic defciency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 98: 13282-13287.
33. Toietta, G, Mane, V P, Norona, WS, Finegold, MJ, Ng, P, McDonagh, AF et al. (2005). Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 102: 3930-3935.
34. Brunetti-Pierri, N, Nichols, TC, McCorquodale, S, Merricks, E, Palmer, DJ, Beaudet, AL et al. (2005). Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum Gene Ther 16: 811-820.
35. Brunetti-Pierri, N, Stapleton, GE, Palmer, DJ, Zuo, Y, Mane, VP, Finegold, MJ et al. (2007). Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther 15: 732-740.
36. Koizumi, N, Yamaguchi, T, Kawabata, K, Sakurai, F, Sasaki, T, Watanabe, Y et al. (2007). Fiber-modifed adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 178: 1767-1773.
37. Sakurai, H, Tashiro, K, Kawabata, K, Yamaguchi, T, Sakurai, F, Nakagawa, S et al. (2008). Adenoviral expression of suppressor of cytokine signaling-1 reduces adenovirus vector-induced innate immune responses. J Immunol 180: 4931-4938.
38. Delgado, M and Ganea, D (2001). Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. Arch Physiol Biochem 109: 377-382.
39. Delgado, M and Ganea, D (2003). Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor κB-dependent transcriptional activity. Biochem Biophys Res Commun 302: 275-283.
40. Muruve, DA, Cotter, MJ, Zaiss, AK, White, LR, Liu, Q, Chan, T et al. (2004). Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 78: 5966-5972.
41. Shayakhmetov, DM, Li, ZY, Ni, S and Lieber, A (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fber-modifed vectors. J Virol 78: 5368-5381.
42. Koizumi, N, Kawabata, K, Sakurai, F, Watanabe, Y, Hayakawa, T and Mizuguchi, H (2006). Modifed adenoviral vectors ablated for coxsackievirus- adenovirus receptor, αv integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 17: 264-279.
43. Azzari, C, Rossi, ME, Resti, M, Caldini, AL, Carbonella, R, Ciappi, S et al. (1992). VIP restores natural killer cell activity depressed by hepatitis B surface antigen. Viral Immunol 5: 195-200.
44. Fabricius, D, O'Dorisio, MS, Blackwell, S and Jahrsdörfer, B (2006). Human plasmacytoid dendritic cell function: inhibition of IFN-α secretion and modulation of immune phenotype by vasoactive intestinal peptide. J Immunol 177: 5920-5927.
45. Hansen, JM, Sitarz, J, Birk, S, Rahmann, AM, Oturai, PS, Fahrenkrug, J et al. (2006). Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 26: 992-1003.
46. Palmer, D and Ng, P (2007). Methods for the Production and Characterization of Helper-Dependent Adenoviral Vectors. Cold Spring Harbor Press: Cold Spring Harbor, NY.
47. Palmer, D and Ng, P (2003). Improved system for helper-dependent adenoviral vector production. Mol Ther 8: 846-852.
48. Palmer, DJ and Ng, P (2004). Physical and infectious titers of helper-dependent adenoviral vectors: a method of direct comparison to the adenovirus reference material. Mol Ther 10: 792-798.